Trump Brothers’ $9.6 Million Stock Windfall: A Closer Look at Dominari Holdings
Donald Trump Jr. and Eric Trump are poised to potentially sell a combined $9.6 million worth of stock in Dominari Holdings, a Nasdaq-listed company headquartered in Trump Tower. This opportunity arises from their brief tenure—approximately 10 weeks—on the company’s advisory board, during which they were each granted 1 million shares. Additionally, they each purchased 216,138 shares and secured warrants for an extra 432,000 shares through a $1 million private placement.
Under standard SEC regulations, shares acquired via private placements are subject to a six-month holding period before they can be sold on the public market. However, Dominari Holdings recently filed a resale registration with the SEC, which, if approved, would allow the Trump brothers and other shareholders to sell their shares sooner.
As of the latest available data, Dominari Holdings’ stock closed at $4.79 per share, valuing each brother’s holdings (excluding warrants) at approximately $5.8 million. Of this amount, $4.79 million is directly linked to the advisory board compensation.
The timing of their stock acquisition and the subsequent announcement of their advisory roles have drawn scrutiny. Reports indicate that Dominari Holdings’ stock experienced a significant surge following the announcement, raising questions about the sequence of events and potential implications.
Dominari Holdings, formerly known as AIkido Pharma, has undergone a strategic shift, now focusing on wealth management, investment banking, and related sectors. The company’s decision to appoint the Trump brothers to its advisory board appears to be part of this broader repositioning strategy.
As the SEC reviews the resale registration, the potential sale of these shares by Donald Trump Jr. and Eric Trump remains a topic of interest, highlighting the intersection of business decisions and public scrutiny.
